TD Cowen Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $63
TD Cowen Reaffirms Their Buy Rating on Evolent Health (EVH)
Evolent Health Analyst Ratings
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
TD Cowen Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $63
TD Cowen Sticks to Their Buy Rating for Evolent Health (EVH)
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
J.P. Morgan Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $45
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $33
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Announces Target Price $33
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
JMP Securities Maintains Evolent Health(EVH.US) With Buy Rating, Raises Target Price to $43
Evolent Health Buy Rating Affirmed With Increased Price Target Amid Growth Prospects and M&A Speculation
Evolent Health Is Maintained at Buy by Truist Securities
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating
Evolent Health Price Target Maintained With a $42.00/Share by RBC Capital
Evolent Health Analyst Ratings
RBC Capital Reiterates Outperform on Evolent Health, Maintains $42 Price Target
Truist Financial Sticks to Its Buy Rating for Evolent Health (EVH)